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Abstract
Anterior pituitary cell turnover occurring during female sexual cycle is a poorly understood process that involves complex
regulation of cell proliferation and apoptosis by multiple hormones. In rats, the prolactin (PRL) surge that occurs at
proestrus coincides with the highest apoptotic rate. Since anterior pituitary cells express the prolactin receptor (PRLR), we
aimed to address the actual role of PRL in the regulation of pituitary cell turnover in cycling females. We showed that acute
hyperprolactinemia induced in ovariectomized rats using PRL injection or dopamine antagonist treatment rapidly increased
apoptosis and decreased proliferation specifically of PRL producing cells (lactotropes), suggesting a direct regulation of
these cell responses by PRL. To demonstrate that apoptosis naturally occurring at proestrus was regulated by transient
elevation of endogenous PRL levels, we used PRLR-deficient female mice (PRLRKO) in which PRL signaling is totally
abolished. According to our hypothesis, no increase in lactotrope apoptotic rate was observed at proestrus, which likely
contributes to pituitary tumorigenesis observed in these animals. To decipher the molecular mechanisms underlying PRL
effects, we explored the isoform-specific pattern of PRLR expression in cycling wild type females. This analysis revealed
dramatic changes of long versus short PRLR ratio during the estrous cycle, which is particularly relevant since these isoforms
exhibit distinct signaling properties. This pattern was markedly altered in a model of chronic PRLR signaling blockade
involving transgenic mice expressing a pure PRLR antagonist (TGD1–9-G129R-hPRL), providing evidence that PRL regulates the
expression of its own receptor in an isoform-specific manner. Taken together, these results demonstrate that i) the PRL
surge occurring during proestrus is a major proapoptotic signal for lactotropes, and ii) partial or total deficiencies in PRLR
signaling in the anterior pituitary may result in pituitary hyperplasia and eventual prolactinoma development, as observed
in TGD1–9-G129R-hPRL and PRLRKO mice, respectively.
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Introduction
Prolactin (PRL) is a hormone secreted mainly by lactotropes in
the anterior pituitary gland. This hormone is involved in several
physiological functions, including mammopoiesis, lactogenesis and
reproduction [1] although it has also been implicated in the
development of various peripheral tumors. In breast and prostate
cancers, where local PRL production has been demonstrated, its
proliferative potential via an autocrine/paracrine mechanisms has
been proposed to contribute to tumor development and progres-
sion [2,3,4,5,6,7].
Prolactinomas are benign tumors that constitute approximately
one third of pituitary tumors [2]. One of the main characteristics
of prolactinomas is that they rarely undergo malignant transfor-
mation or local invasiveness [2]. It has been proposed that
prolactinomas have a monoclonal origin and that alterations in
cell cycle regulation lead to expansion of an original mutated cell
[8,9]. Although several oncogenes are expressed in these
adenomas, and various mutations have been associated with
familial cases of anterior pituitary tumors, the mechanisms leading
to sporadic adenoma formation, the most frequent presentation of
the pathology in this gland, are currently unknown [2,8,9].
Considering that the anterior pituitary is a gland with considerable
plasticity [10], alterations in the mechanisms that physiologically
regulate anterior pituitary cell turnover can be involved in the
pathogenesis of pituitary tumors. Since all endocrine pituitary
cells, including lactotropes, express prolactin receptors (PRLR)
[11,12], PRL is assumed to participate in the regulation of anterior
pituitary functions including tissue homeostasis. Hence, alterations
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of PRLR signaling may play a role in anterior pituitary tumor
development.
According to the effects described for PRL in the majority of its
target tissues [6,13,14,15,16,17,18], it was initially proposed that
this hormone may exert trophic action on anterior pituitary cells
[19,20,21,22]. However, studies using PRLR knockout
(PRLRKO) mice subsequently showed that PRL actually exerts
an opposite effect on lactotropes, since these mice develop
pituitary adenomas [23]. Using a specific PRLR antagonist able
to partially block PRLR signaling in biological systems where both
the ligand and the receptor are expressed, we recently demon-
strated that unlike what happens in most other tissues, PRL
induced apoptosis and reduced proliferation of anterior pituitary
cells from male rats, acting through an autocrine/paracrine
mechanism [24].
In females, however, regulation of pituitary homeostasis is a
more complex process that remains uncharacterized. The anterior
pituitary gland of female rodents undergoes constant remodeling
during each estrous cycle. Furthermore, under specific conditions
such as pregnancy and lactation, it also responds to particular
physiological demands [10,25,26]. Anterior pituitary cell turnover
is about 3% per day in female rats [10]. During each estrous cycle,
a peak of proliferation occurs specifically at estrus [27,28,29]
whereas the highest rate of apoptosis is observed at proestrus
[30,31]. This cell turnover is a tightly regulated process in which
several factors, e.g. estradiol [25,32], dopamine [33,34], and
16 kDa PRL [35], were demonstrated to participate. Interestingly,
during the afternoon of proestrus, i.e. when the rate of apoptosis is
the highest, there is a concomitant peak of serum PRL in response
to high circulating levels of estrogens [36]. We hypothesize that the
proestrus surge of PRL release participates in anterior pituitary cell
renewal that occurs during the estrous cycle.
The PRLR is expressed as different isoforms generated by
alternative splicing. They include one long (PRLRlong) and one
short (PRLRshort) isoform in rats and one long and three short (S1,
S2 and S3) isoforms in mice [2]. The long and short isoforms differ
in the polypeptide chain of the intracellular domain; hence, they
are all able to bind PRL equally but exhibit different abilities to
trigger the canonical PRLR intracellular signaling pathways
[4,37,38]. Although PRLR isoforms are usually co–expressed in
the same tissue [38,39], one of the isoforms often predominates
over the others, depending on the tissue and the physiological
context [37,39]. For example, in the mouse ovary, PRLRlong is the
most abundantly expressed isoform, followed by S2 and S3
PRLRshort isoforms [40]. Furthermore, the ratio of PRLRlong
versus PRLRshort expression varies during the estrous cycle, as
showed in the rat ovary [41]. Transgenic mice expressing only the
PRLRshort exhibit impaired follicular and corpora lutea develop-
ment [42,43] whereas mice expressing only the endogenous
PRLRlong present normal follicular but abnormal corpus luteum
development. This suggests that the expression of both PRLR
isoforms is necessary for physiological completion of this process
[41].
Regarding the pituitary, expression of long and short isoforms
has been reported in the rat, the PRLRlong being the most
abundant. In the male mouse pituitary, the predominant form is
also the PRLRlong [24]. In the female mouse pituitary, PRLR
expression was studied in prepuberal mice, where the short
isoform was found to be predominant [44]. In mature female
mice, expression of the four PRLR isoforms has been reported
[45]. However, data on PRLR expression in cycling female mice
are lacking, which makes delineating the actual involvement of
PRLR signaling in pituitary homeostasis during each estrous cycle
elusive. Indeed, PRL may autoregulate its actions on the anterior
pituitary by modulating its own expression, its own secretion [46]
and/or the isoform-specific expression of its receptor, as described
in a variety of other tissues [37,39]
The aim of the present study was to address the role of PRL in
the regulation of anterior pituitary cell turnover and PRLR
expression in the anterior pituitary of cycling females. To that end,
we designed a series of in vivo experiments involving normal rat/
mice as well as two genetically-modified mouse models in which
PRLR signaling is down-regulated or totally abolished.
Materials and Methods
Drugs and reagents
All drugs, media and supplements were obtained from Sigma
(St. Louis, MO, USA) except fetal calf serum (Natocor, Co´rdoba,
Argentina), amphotericin B, essential aminoacids and gentamicin
(Invitrogen, Carlsbad, CA, USA), all terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick end-labeling
(TUNEL) reagents (Roche Molecular Biochemicals, Mannheim,
Germany) and the reagents described below.
Animals
Mice and rats were housed in controlled conditions of light (12-
hour light-dark cycles) and temperature (20–22uC), and were fed
ad libitum.
Ethical statements
This study was approved by the Comite´ Re´gional d’E´thique
pour l’Expe´rimentation Animale, Ile-de-France, Universite´ Paris
Descartes (authorization number: P2.VG.120.09) and by the
Animal Care Use Committee of the School of Medicine,
University of Buenos (CICUAL), University of Buenos Aires,
approval ID: Res. (CD) Nu 2831/10.
In vivo treatments of female rats
Adult Wistar female rats (200–220 g) were ovariectomized
(OVX) under ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg,
i.p.) anesthesia and ketoprofen (5 mg/kg) for analgesia, 2 weeks
before treatments.
OVX rats were injected with ovine PRL (oPRL) (1 mg/kg, i.p)
or vehicle (NaCl 0.9%). This dose of PRL results in serum
concentrations of ,700 ng/ml at 30 min and ,500 ng/ml 1 h
after i.p. administration [47]. Rats were co-injected with
bromodeoxyuridine (BrdU, 50 mg/kg) [24] and euthanized 6 h
later.
In other experiments, rats were injected with the dopamine D2
receptor (D2R) antagonist sulpiride (5 mg/kg, i.p.) [48] and BrdU
(50 mg/kg) and killed 6 h later.
Anterior pituitary glands were removed within minutes after
decapitation. Cells were dispersed and fixed. For this procedure,
anterior pituitary glands were washed with Dulbecco Eagle’s
Modified Medium (DMEM) containing 3 mg/ml bovine serum
albumin (DMEM-BSA). Then, anterior pituitaries were cut into
small fragments and dispersed enzymatically by successive
incubations in DMEM-BSA containing 0.75% trypsin, 10%
charcoal-dextran-adsorbed fetal calf serum (FCS) and 45 U/ml
deoxyribonuclease type I (DNAse). Finally, the cells were dispersed
by extrusion through a Pasteur pipette in Krebs buffer without
Ca2+ and Mg2+. Dispersed cells were washed and resuspended in
DMEM with 10% FCS. In all procedures, cell viability as assessed
by trypan blue exclusion was over 85%. Cells were fixed using ice-
cold 70% ethanol in PBS overnight at 220uC [35].
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PRLRKO mice
To evaluate the role of PRLR signaling in the control of
anterior pituitary cell renewal during the estrous cycle, we used
PRLRKO mice in which PRLR signaling is totally abolished due
to the absence of PRLR expression. These mice were generated on
C57BL/6 genetic background as previously described [49]. Two
to 3 month-old mice were used, because they do not present
pituitary enlargement at this age [49], and consequently have
conserved anterior pituitary cell populations. PRLRKO and wild
type (WT) littermates cycling female mice were injected with BrdU
(50 mg/kg, i.p) 24 h before euthanasia. Animals were euthanized
by cervical dislocation at diestrus or proestrus, as determined by
daily vaginal smears. Pituitaries were removed within minutes,
weighed and processed for TUNEL assay, BrdU incorporation
detection and PRL co-immunostaining.
Transgenic mice expressing the pure PRLR antagonist
D1–9-G129R-hPRL
To evaluate the role of PRL in the control of PRLR expression,
we used transgenic female mice in which systemic expression of
the pure PRLR antagonist D1–9-G129R-hPRL impairs PRLR
signaling (TGD1–9-G129R-hPRL mice). These mice were generated
on BALB/c-J background as previously described [7]. As young
but not old TG female mice have altered estrous cycle [50], we
used 12 month-old TGD1–9-G129R-hPRL female mice and WT
littermates, which were euthanized at proestrus or diestrus, then
pituitaries were removed as described above. After neurointer-
mediate lobe removal, anterior pituitaries were processed for RNA
extraction.
Detection of BrdU incorporation by flow cytometry
(FACS)
In rats, BrdU incorporation was detected by FACS. After
fixation in ice-cold 70% ethanol by gently vortexing, cells were
centrifuged and incubated in a solution containing 1% parafor-
maldehyde (PFA), 0.01% Tween-20, 1 h at 20uC. Then, the cells
were incubated with DNAse I 100 U/ml diluted in NaCl 0.15 M,
MgCl2 4.2 M pH 5 for 25 min at 37uC, centrifuged and
incubated with a fluorescein (FITC)-conjugated anti-BrdU anti-
body or the corresponding isotype control (BD Bioscience, San
Jose, CA, USA) for 40 min at 20uC. Cells were washed with PBS
and incubated with 1% PFA for 15 min. After centrifugation, cells
were resuspended in PBS until FACS analysis. Fluorescence
intensity of $6,000 gated cells/tube was analyzed by FACS using
a FACScan (BD Bioscience, San Jose, CA, USA). Analysis of BrdU
positive cells was performed using WinMDI 98 software.
Cell-cycle analysis by FACS
After fixation in ice-cold 70% ethanol, anterior pituitary cells
from OVX or treated- OVX rats, were centrifuged and DNA was
stained with propidium iodide (PI, 50 mg/ml) in PBS containing
ribonuclease (10 mg/ml) for 20 min at 37uC [24,35]. After
centrifugation, immunostaining of lactotropes was performed
using guinea pig antiserum directed against rat PRL (Dr.
A.Parlow, National Hormone and Pituitary Program, Torrance,
CA, USA) (1:2,000, 1 h at 37uC), washed in PBS and then
incubated with a FITC-conjugated anti-guinea pig antibody
(Chemicon International, Temecula, CA., USA) (1:75, 40 min at
37uC). For isotype controls, the cells were incubated with guinea
pig serum instead of PRL antiserum [51]. Cells were washed,
resuspended in PBS and analyzed by FACS. Fluorescence
intensity of $10,000 gated cells/tube was analyzed using a
FACScan.
Cells with a PI staining intensity lower than the G0/G1 peak
were considered hypodiploid. Analysis of DNA content and PRL-
positive cell determination were performed using WinMDI 98
software. The analysis of hypodiploidy and cell cycle in lactotropes
was performed gating the PRL-positive population. Determination
of cells in Sub G0/G1 (hypodiploid cells), G0/G1, S and G2/M-
phases of the cell cycle, was performed using WinMDI 98 and
Cylcherd 1.2 softwares [24,35].
TUNEL assay and detection of BrdU incorporation in
anterior pituitary sections
Pituitaries from PRLRKO and WT cycling female mice were
removed immediately after euthanasia, weighed, fixed in 4% PFA
in PBS (pH 7.4) for 4 h and embedded in paraffin. Sections (4 mm)
were deparaffinized in xylene and rehydrated in graded ethanol.
Antigen retrieval was performed by microwave irradiation. For
TUNEL assay, DNA strand breaks were labeled with digoxigenin-
deoxyuridine triphosphate using terminal deoxynucleotidyl trans-
ferase (0.18 U/ml) according to the manufacturer’s protocol. After
incubation in PBS with 10% sheep serum for 90 min, sections
were incubated with antidigoxygenin- FITC antibody (1:10) to
detect incorporation of nucleotides into the 39-OH end of
damaged DNA [24,52].
For BrdU incorporation detection, slides were permeabilized
with PBS-Triton X-100 0.1% for 17 min at RT. After incubation
with 3% BSA in PBS-Triton for 30 min, sections were incubated
with anti BrdU antibody in DNAse solution (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) according to manufacturer’s
protocol [24]. Sections were washed and incubated with an anti-
mouse FITC secondary antibody (Chemicon International,
Temecula, CA., USA) 1:200 in PBS-Triton 0.5%, with 1% horse
serum.
In order to identify TUNEL-positive or BrdU-positive lacto-
tropes, after washing with PBS-Triton 0.5%, slides were incubated
with 10% goat serum in PBS-Triton 0.5% for 90 min followed by
an anti-mouse PRL antiserum (Dr. A.Parlow, National Hormone
and Pituitary Program) 1:200 in PBS-Triton 0.5% overnight. After
washing, slides were incubated with an anti rabbit secondary
antibody conjugated with rhodamine (Chemicon). Sections were
mounted with Vectashield (Vector Laboratories, Inc., Burlingame,
CA, USA) containing 4, 6 diamidino-2-phenylindoledihydrochlor-
ide (DAPI) for DNA staining and visualized in a fluorescent light
microscope (Axiophot). Since the number of TUNEL-positive or
BrdU-positive cells in sections from in vivo studies were very low,
apoptosis and proliferation were expressed as the number of
TUNEL-positive cells/field, BrdU-positive cells/field, TUNEL-
positive PRL-positive cells/field (TUNEL-positive lactotropes),
BrdU-positive PRL-positive cells/field (BrdU-positive lactotropes)
or TUNEL-positive PRL negative cells/field (TUNEL-positive
non lactotrope cells) and BrdU-positive PRL negative cells/field
(BrdU-positive non lactotrope cells) as previously described
[24,52]. Cells from the neurointermediate lobe were excluded
from the count. TUNEL-positive or BrdU-positive anterior
pituitary cells were counted in 30–40 fields (x 400) of anterior
pituitary sections from each mouse. The mean of TUNEL-positive
cells or TUNEL-positive lactotropes/field or BrdU-positive cells or
BrdU-positive lactotropes/field from each mouse was considered
as an individual value [24,52].
RNA extraction and Real-Time PCR
Anterior pituitaries from TG and WT cycling female mice were
removed, washed in RNAeasy Solution (Qiagen Inc., Santa
Clarita, CA, USA) and immediately frozen in liquid nitrogen.
RNA was extracted using RNAeasy Micro Kit (Qiagen) following
Prolactin Induces Apoptosis of Lacotropes
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the manufacturer’s protocol. Briefly, frozen anterior pituitaries
were homogenized using a cold mortar and pestle and placed in
350 ml of RTL lysis buffer (Qiagen) containing b-mercaptoetha-
nol, re-homogenized with a needle and centrifuged. The
supernatant was washed with 70% ethanol, centrifuged, and
transferred onto an RNAeasy spin column (Qiagen). RNA was
collected with 14 ml RNAse-free water and stored at 280uC.
Reverse transcription was performed using SuperScript II Reverse
Transcriptase according to the manufacturer’s protocol. One
hundred twenty five ng of total RNA were reverse transcribed.
After incubation for 5 min at 65uC with 1 ml oligo (dT) and 1 ml of
dNTP Mix, RNA samples were incubated for 2 min at 42uC with
a mix containing DTT and RNAse OUT (Invitrogen). After
addition of 1 ml SuperScript II RT (Invitrogen), samples were
incubated for 50 min at 42uC and the reaction was heat-
inactivated (70uC for 15 min). Finally, samples were treated with
RNAse H (Invitrogen) to remove any possible RNA complemen-
tary to cDNA.
For Real Time PCR, we used forward primers mapping mouse
PRLR extracellular domain (ECD) common to all isoforms, and a
reverse primer specific to intracellular domains (ICD) of mouse
PRLRlong, S1, S2 or S3 PRLRshort isoforms (Table 1) [24];
cyclophilin was used as a reference as previously described [24,53].
All primers were obtained from Eurogentec (Lie`ge, Belgium).
Real Time PCR was performed using an Applied Biosystems
7300 Real-Time PCR System. For each reaction, 25 ml of solution
containing 5 ml cDNA, 0.25 ml of 20 mM forward and reverse
primers and 12.5 ml Power SyberGreen PCR Master Mix (Applied
Biosystems, Carlsbad, CA, USA) were used. All reactions were
performed in duplicate. Negative controls included amplification
of RNA (without reverse transcription) and water. Amplification
was initiated by a 2 min pre-incubation at 50uC, followed by 40
cycles at 95uC for 30 s, 60uC for 1 min, 95uC for 15 s, 60uC for
30 s, terminating at 95uC for the last 15 s (melting). We used the
22DCt method to determine the effect of the experimental
treatment (presence of the antagonist in transgenic mice or estrous
cycle variation) on the expression of the candidate internal control
gene. The expression for cyclophilin was not different in WT and
TG transgenic mice or between different estrous cycle stages.
Validation of the 22DCt method in our experiments was performed
by determining that amplification efficiencies of PRLRlong,
PRLRshort isoforms and cyclophilin were similar, following the
procedure published by Livak and Schmittgen et al [54]. Linearity
of real-time RT-PCR signaling was determined with wide-range
serial dilutions of reference cDNA and linear correlations were
found between the amount of cDNA and the Ct for the duration of
at least 40 real-time RT-PCR rounds. Expression levels were
normalized to mouse cyclophilin expression, performed in parallel
as endogenous control [54]. Real Time-PCR data were analyzed
by calculating the 22DCt value for each experimental unit, Ct
being the cycle threshold number and DCt being the difference
between the Ct values for total or each PRLR isoform and
cyclophilin [24].
Determination of PRL serum levels by
Radioimmunoassay (RIA)
Serum PRL levels were measured by RIA using reagents
provided by the National Institute of Diabetes and Digestive and
Kidney Diseases, National Hormone and Pituitary Program (Dr.
A. F. Parlow, Torrance, CA). Results were expressed in
nanograms per milliliter in terms of rat PRL RP3. Intra- and
interassay coefficients of variation were 6.9 and 11.6%, respec-
tively [55].
Statistical Analysis
Data were expressed as mean 6 SEM. The significance of the
differences between means was determined by Student’s t test or
two-way ANOVA followed by Tukey’s test. Differences were
considered significant if p,0.05. Statistical analyses were per-
formed using GraphPad Prism 6 software.
Results
Acute PRL injections regulate proliferation and apoptosis
of female rat lactotropes
In cycling females, anterior pituitary cells are exposed to high
PRL levels during the afternoon of proestrus, the stage of the
estrous cycle with the highest rate of apoptosis and the lowest rate
of proliferation. Therefore, to examine whether PRL acutely
affects proliferation or apoptosis of anterior pituitary cells, OVX
rats were injected with oPRL and euthanized 6 h later [47].
Ovariectomy was performed to ensure low and stable plasma
levels of endogenous PRL and to avoid effects of gonadal steroids
on anterior pituitary cell apoptosis and proliferation
[32,56,57,58,59]. Acute oPRL treatment decreased the prolifer-
ation rate of anterior pituitary cells as determined by monitoring
BrdU-positive cells (Fig. 1). In contrast, apoptosis was increased by
oPRL as determined by the percentage of cells with hypodiploid
DNA content (Fig. 2A). Cell-cycle analysis showed that this effect
was correlated to a decreased number of cells in G2/M phase,
without changes in the percentage of cells in G0/G1 or S-phase
(Fig. 2 B–D). To investigate whether PRL specifically regulates
lactotrope renewal, we characterized cell cycle progression and
hypodiploid content of DNA in cells positively stained with an
anti-PRL antibody. Lactotrope apoptosis was higher in rats
injected with oPRL than in control OVX animals (Fig. 3A, G).
We also observed that oPRL reduced the percentage of lactotropes
in G2/M with borderline significance (p = 0.053) (Fig. 3D),
without other alteration in the progression of the cell cycle in
the lactotrope subpopulation (Fig 3 B, C). The proapoptotic and
antiproliferative effects of oPRL were not observed in the non-
lactotrope subpopulation (Fig. 3E–F and G).
Endogenous PRL regulates apoptosis and proliferation of
female rat anterior pituitary cells
Besides its inhibitory action on PRL secretion, dopamine
modulates anterior pituitary cell turnover by inducing apoptosis
and decreasing proliferation of lactotropes [34,60]. Hypothalamic
dopaminergic neurons express PRLR, and variations in serum
PRL levels induce changes in the dopaminergic tone [60]. Since
PRL administration may lead to an increase in dopamine reaching
Table 1. Primers used for real time PCR analysis of PRLR
isoform expression.
Primer Sequence
PRLR ECD Forward 59-TAAAAGGATTTGATACTCATCTGCTAGAG-39
PRLR ICD Long Reverse 59-TGTCATCCACTTCCAAGAACTCC-39
PRLR ICD S1 Reverse 59-CATAAAAACTCAGTTGTTGGAATCTTCA-39
PRLR ICD S2 Reverse 59-GGAAAAAGACATGGCAGAAACC-39
PRLR ICD S3 Reverse 59-AGTTCCCCTTCATTGTCCAGTTT-39
ECD: extracellular domain; ICD: intracellular domain
doi:10.1371/journal.pone.0097383.t001
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the anterior pituitary [36], dopamine could be involved in changes
in anterior pituitary cell turnover induced by PRL injection. To
circumvent this possibility, we induced hyperprolactinemia in
OVX rats by the administration of sulpiride, a D2R antagonist. As
expected, sulpiride administration increased serum PRL levels up
to ,400 ng/ml (Fig. 4A). Similarly to what was observed in rats
injected with oPRL, sulpiride administration decreased BrdU
incorporation (Fig. 4B) and increased apoptosis of anterior
pituitary cells (Fig. 4C). These results suggest that PRL exerts a
direct antiproliferative and proapoptotic effect on anterior
pituitary cells, independently of dopamine action.
The absence of PRLR signaling abrogates anterior
pituitary cell apoptosis during the estrous cycle
In both mice [61,62] and rats [36], serum PRL levels are
relatively constant all-over the estrous cycle, except at proestrus,
when a sharp increase in PRL secretion occurs in response to high
circulating levels of estrogens [36]. At that time, the proliferation
index in rats is the lowest. To evaluate if the antiproliferative effect
of PRL is implied in the control of the proliferation rate that
occurs at proestrus, we studied the effects of PRLR signaling on
pituitary cell proliferation in WT and PRLRKO mice sacrificed at
diestrus or proestrus. As previously reported, no difference in body
or pituitary weight was observed in 2–3 month old PRLRKO mice
versus WT littermates (Fig. 5A, B) [23]. Proliferation was assessed
by in vivo BrdU (24 h) incorporation (Fig. 5). In WT mice, there
were no differences in the proliferative index of total anterior
pituitary cells, lactotropes or non-lactotrope cells between diestrus
and proestrus, although the global trend was a decrease in
proestrus (Fig. 5C–E). In PRLRKO mice, we again observed no
significant difference of proliferation in the various cell popula-
tions, but interestingly the trend was to increase in proestrus,
opposite to that seen in WT mice (Fig. 5C–E).
The proestrus peak in circulating levels of PRL coincides with
the highest rate of apoptosis in the rat anterior pituitary [25]. To
evaluate whether the proapoptotic effect of PRL is involved in
anterior pituitary cell renewal, especially at proestrus, we
determined the rate of apoptosis in the anterior pituitary gland
from WT and PRLRKO mice euthanized at proestrus or diestrus
(Fig. 6A–C). In WT mice apoptosis was higher at proestrus than at
diestrus (Fig. 6A). When PRLR signaling was totally abolished (i.e.
in PRLRKO mice), the number of apoptotic anterior pituitary
cells was markedly decreased compared to WT mice both at
diestrus and at proestrus (Fig. 6A). In fact, the high apoptotic rate
of total anterior pituitary cells and lactotropes normally observed
at proestrus was absent in PRLRKO mice (Fig. 6A, 6B). In
contrast, no differences in the apoptotic rate of non-lactotrope cells
were observed between diestrus and proestrus (Fig. 6C). Taken
together, these results suggest that i) the main subpopulation
implied in mouse anterior pituitary cell turnover at proestrus is the
lactotrope subpopulation, and ii) PRLR signaling is a major
regulator of cell apoptosis underlying this process.
Prolactin regulates expression of its own receptor during
the estrous cycle
To further investigate the effects of PRL on the control of
pituitary cell homeostasis at proestrus, we determined the
expression profile of PRLR isoforms in anterior pituitaries of
female mice when apoptosis occurs. To that end, we used
transgenic mice expressing the pure PRLR antagonist D1-9-
G129R-hPRL, which competes with endogenous PRL for PRLR
activation [7,24]. In agreement with previous results involving
male mice [24], we observed that chronic blockade of PRLR
signaling by the PRLR antagonist resulted in increased pituitary
weight in TGD1–9-G129R-hPRL female mice compared to WT
littermates (Fig. 7B), whereas body weight was unaffected (Fig. 7A).
Using isoform-specific qPCR, we were able to detect three
PRLR isoforms in the anterior pituitary from both WT and TGD1–
9-G129R-hPRL mice (PRLRlong, PRLRshort S3 and, to a much lesser
extent, PRLRshort S2). The ratios of PRLRlong/PRLRshort expres-
sion in the different experimental conditions (WT and TGD1–9-
G129R-hPRL at proestrus or diestrus) that were analyzed in this study
are shown in Table 2. In WT mice, PRLRlong is the predominant
isoform (36-fold over PRLRshort) expressed at diestrus. The
expression of both PRLRlong (Fig. 7C) and PRLRshort S3
(Fig. 7D) increased at proestrus, but with a much higher amplitude
for the latter; as a result, the ratio of both isoforms dropped to
nearly 1:1. In TGD1–9-G129R-hPRL mice, expression of both
PRLRlong and PRLRshort S3 were dramatically increased with
respect to WT mice at diestrus (Fig. 7C, 7E), but again PRLRlong
was very predominant (57-fold). At proestrus, in contrast to WT
mice, expression of PRLRlong decreased compared to diestrus,
while PRLRshort S3 expression was unchanged. Taken together,
these results show that the expression of PRLR varies during the
estrous cycle in an isoform-specific manner, which ultimately
affects the long/short isoform ratio. Chronic blockade of PRLR
signaling by the antagonist alters the isoform-specific regulation
that normally occurs during the estrous cycle, which strongly
suggests that PRL modulates the expression of its own receptor in
the pituitary.
Discussion
The control of cell turnover in the anterior pituitary has been
extensively studied by several groups including ours, focusing
mainly on the endocrine effect of upstream neurotransmitters and
peripheral hormones/cytokines such as dopamine [33,34], estra-
diol [31,32,51,63], TNF-a [56,57], FasL [58,59], TGF-b [48,55]
or IL-6 [64] to cite only a few. However, the autocrine or
paracrine regulation of pituitary cell turnover by pituitary
hormones themselves is less well understood. Recently, it has
been shown that GH controls somatotrope function via an
intracrine mechanism and that deregulation of this process is
involved in the development of GH-secreting tumors [65]. In the
Figure 1. PRL decreases anterior pituitary cell proliferation in
vivo. Ovariectomized rats (n = 4 rats/group) were injected with oPRL
(1 mg/kg, 6 h) or saline and BrdU (50 mg/kg, 6 h). Proliferation rate was
determined by the detection of BrdU incorporation and FACS analysis.
Each column represents the mean 6 SEM of the percentage of BrdU-
positive cells. *p,0.05 vs. respective control (CTRL) animals injected
with vehicle, Student’s t test.
doi:10.1371/journal.pone.0097383.g001
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Figure 2. PRL increases anterior pituitary cells apoptosis in vivo and decreases the percentage of total anterior pituitary cells in G2/
M-phase. Ovariectomized rats (n = 12 rats/group) were injected with oPRL (1 mg/kg, 6 h) or saline. A: Apoptosis was determined as the percentage
of hypodiploid cells, using PI and FACS. Each column represents the mean 6 SEM of the percentage of sub G0–G1 cells. *p,0.05 vs. respective
control animals injected with vehicle, Student’s t test. B–D: Cell cycle was analyzed by FACS using PI. Each column represents the mean6 SEM of the
percentage of cells in G0/G1-phase (B), cells in S-phase (C) and cells in G2/M-phase (D). * p,0.05 vs. control animals injected with vehicle, Student’s t
test. E: Representative histograms showing hypodiploidy or cells in each cell cycle stage in CTRL and oPRL-treated animals.
doi:10.1371/journal.pone.0097383.g002
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female anterior pituitary, lactotropes represent up to the 50% of
the hormone-secreting cells [36] and are the population with the
highest plasticity in the gland, suffering periods of proliferation and
apoptosis that are tightly regulated throughout the estrous cycle
[10,25]. Prolactin may act on PRL-producing cells as well as on
neighbor, non-lactotrope cells, considering that all of them express
the PRLR [11,12,21,41]. In fact, PRL is known to inhibit its own
synthesis and secretion at the lactotrope level [46]. Furthermore,
we recently observed that PRL controlled anterior pituitary cell
turnover in male mice by an autocrine/paracrine mechanism [24].
Figure 4. Sulpiride decreases anterior pituitary cell proliferation in vivo. Ovariectomized rats (n = 5–7 rats/group) were injected with
sulpiride (5 mg/kg, 6 h) or saline, and with BrdU (50 mg/kg, 6 h). A: Sulpiride treatment induced hiperprolactinemia in OVX rats. Each column
represents serum PRL levels6 SEM in CTRL or sulpiride-treated animals. *p,0.05 vs. CTRL animals injected with vehicle, Student t test. B: Proliferation
rate determined by the detection of BrdU incorporation and FACS. Each column represents the mean6 SEM of the percentage of BrdU-positive cells.
*p,0.05 vs. CTRL animals injected with vehicle, Student t test. C: Apoptosis was determined by FACS, using PI. Each column represents the mean 6
SEM of the percentage of sub-G0-G1 cells. **p,0.01 vs. CTRL animals injected with vehicle, Student’s t test. D: Representative histograms showing
hypodiploidy in CTRL and sulpiride-treated animals.
doi:10.1371/journal.pone.0097383.g004
Figure 3. PRL increases lactotrope apoptosis in vivo. Lactotropes were identified by PRL immunostaining and analyzed by FACS. Apoptosis and
cell cycle analysis were performed in the PRL-positive subpopulation. A: Apoptosis was determined by FACS using PI. Each column represents the
mean6 SEM of the percentage of sub cells in G0–G1. *p,0.05 vs. CTRL animals injected with vehicle, Student’s t test. B–D: Cell cycle was analyzed by
FACS using PI. Each column represents the mean6 SEM of the percentage of cells in G0/G1-phase (B), cells in S-phase (C) and cells in G2/M-phase (D)
p = 0.05 for G2/M in oPRL respect to CTRL, Student’s t test. E–F: oPRL treatment did not change the apoptosis rate (E) or the percentage of cells in G2/
M in the PRL-negative subpopulation. G: Representative histograms showing hypodiploidy or cells in each stage of the cell cycle in CTRL and PRL-
treated animals.
doi:10.1371/journal.pone.0097383.g003
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In contrast to what occurs in males, regulation of pituitary cell
functions during the sexual cycle in rodents depends on short-term
exposure to hormones. For that reason, we directed our studies to
the acute effects of PRL on anterior pituitary cell turnover in order
to determine whether this hormone participates in the control of
pituitary remodeling. We found that acute hyperprolactinemia,
induced either by PRL administration or by dopamine receptor
antagonism, reduced cell proliferation and increased apoptosis,
indicating that these effects of PRL are dopamine-independent.
Also, we found that PRL increased the apoptotic rate and had a
non-significant effect on cell proliferation specifically in lacto-
tropes. In other words, PRL acts as an antiproliferative and
proapoptotic autocrine/paracrine factor in the pituitary, specifi-
cally on lactotrope cells, and this effect occurs after short time
stimulation, as may occur during the estrous cycle.
Therefore, we investigated whether the proestrus surge of PRL
is involved in the regulation of proliferation and apoptosis of the
anterior pituitary gland during the estrous cycle using a mouse
model in which PRLR signaling is totally abolished, i.e. the
PRLRKO mouse. Wild type animals at diestrus were used as
controls, since, at this stage of the cycle, PRL levels are low and,
based on previous reports in rats [28,30], we expected to find basal
levels of proliferation or apoptosis.
Although we did not observe significant differences in the
proliferation index in PRLRKO mice with respect to WT animals,
the sum of our results suggest nevertheless that the peak of PRL
also may contribute to lowering the proliferation rate at proestrus.
In fact, the lack of a significant effect in the proliferation index in
mice during the estrous cycle may be due to the timing of BrdU
injection, which was administered 24 hours before euthanasia i.e.
the day before the expected proestrus or diestrus. Conversely, we
Figure 5. Anterior pituitary cell proliferation in WT and PRLR KOmice at proestrus or diestrus. Wild type and PRLRKO mice (6–10 animals
per group) were injected with BrdU (50 mg/kg, 24 h) and sacrificed at proestrus or diestrus. Proliferation was determined by BrdU incorporation in
tissue sections. A, B: Body weight (A) and pituitary weight (B) of WT and PRLRKO mice euthanized at diestrus or proestrus, expressed as mean6 SEM,
two-way ANOVA. C: Each column represents the media6 SEM of proliferating total anterior pituitary cells (BrdU-positive cells/field). Two-way ANOVA.
D: Each column represents the media 6 SEM of proliferating lactotropes (BrdU-positive PRL positive cells/field), Two-way ANOVA. E: Each column
represents the media 6 SEM of proliferating non-lactotrope cells (BrdU-positive PRL-negative cells/field). Two-way ANOVA. F: Representative
microphotographs of anterior pituitaries from KO mice euthanized at proestrus. Arrow heads indicate BrdU-positive lactotropes. Arrows indicate
BrdU-positive cells.
doi:10.1371/journal.pone.0097383.g005
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observed that the apoptotic rate in the anterior pituitary from
female mice was higher at proestrus with respect to control
animals at diestrus, confirming our expectations. The global
reduction in the anterior pituitary apoptosis rate, and furthermore
the lack of differences in apoptosis between proestrus and diestrus
observed in PRLRKO female mice, strongly suggested that PRL
acts as a proapoptotic signal during the estrous cycle. These
differences in apoptotic rate had no measurable impact on
pituitary weight (Fig. 5B). This is not surprising as we at best
identified 1 or 2 apoptotic cells per field (Fig. 5C, D), suggesting
that apoptosis needs to take place during a certain amount time to
eventually impact on pituitary size or weight. This is supported by
the fact that pituitary hyperplasia develops in .6 month old
PRLRKO mice despite of the fact that significant decrease in
apoptosis is already observed from 2–3 months of age (Fig. 5C).
Accordingly, variations in apoptotic rate occurring during the
estrous cycle (4 days) are probably not sufficient to affect pituitary
weight. No attempt was made in the present study to determine
the absolute number of pituitary cell in each condition. In
summary, this study provides the first evidence that the apoptotic
and antiproliferative effects of PRL participates in the regulation of
anterior pituitary cell turnover during the estrous cycle.
It has been previously shown that the double PRLRKO/
D2RKO mice present more marked pituitary hyperplasia and
increased pituitary weight compared to the single D2RKO
counterpart [23]. Our results may explain why abrogation of
PRLR signaling in PRLKO or PRLRKO mice contributes to
pituitary hyperplasia. PRLRKO female mice develop pituitary
hyperplasia from 6 months of age, whereas male mice do not show
pituitary enlargement until 18 months of age [23]. In females, the
apoptotic and proliferative rates are acutely and closely regulated
at each stage of the estrous cycle. Our results indicate that in
PRLRKO female mice there is a progressive and accumulative
effect due to the lack of PRL apoptotic and antiproliferative
actions in each proestrus. These results also could explain why
PRLRKO female mice develop pituitary hyperplasia earlier than
males, although PRL also plays a key role in regulating pituitary
remodeling in males [24].
Based on the evidence provided here that PRL, like dopamine,
regulates anterior pituitary homeostasis by controlling cell
proliferation and apoptosis, our findings further support the
earlier hypothesis of Schuff et al [23] that a deficiency of these two
individual pathways results in additive effects on the development
of pituitary tumors in double PRLRKO/D2RKO mice. In
accordance with this hypothesis, we also observed that chronic
blockade of PRLR by the antagonist D1-9-G129R-hPRL
increased the pituitary weight in TG female mice.
Based on these results, we propose a general model depicted in
Figure 8. At proestrus, the high circulating levels of estrogens
upregulate PRL secretion [36] which in turn, together with
estradiol itself [32,52], induces apoptosis of anterior pituitary cells.
Furthermore, PRL stimulates dopamine release from hypotha-
lamic dopaminergic neurons to the portal vessels [66,67].
Dopamine reaching the anterior pituitary could also contribute
to the apoptosis [33,34] observed in the gland at this stage of the
estrous cycle. Estradiol also increases anterior pituitary PRL
Figure 6. Apoptosis in lactotropes but not in non-lactotrope cells varies during the estrous cycle and decreases in PRLRKO mice.
Wild type and PRLRKO mice (6–10 animals per group) were euthanized at proestrus or diestrus. Apoptosis was determined by TUNEL assay in tissue
sections. A: Each column represents the media 6 SEM of TUNEL-positive cells/field. *p,0.05 vs. diestrus WT, ‘p,0.01 vs. diestrus WT, ‘‘p,0.01 vs.
proestrus WT. Two-way ANOVA, followed by Tukey’s test. B: Each column represents the media 6 SEM of apoptotic lactotropes (TUNEL-positive PRL-
positive cells/field). *p,0.05 vs. diestrus, ‘‘p,0.01 vs. proestrus WT. Two-way ANOVA, followed by Tukey’s test. C: Each column represents the media
6 SEM of apoptotic non-lactotrope cells (TUNEL-positive PRL-negative cells/field). ‘p,0.05 vs. diestrus WT or proestrus WT. Two-way ANOVA,
followed by Tukey’s test. D: Representative microphotographs of anterior pituitaries from WT mice euthanized at proestrus. Arrow heads indicate a
TUNEL-positive lactotrope.
doi:10.1371/journal.pone.0097383.g006
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cleavage into 16 kDa N-terminal fragments, which in turn induce
apoptosis in an estrogen-dependent manner [35], by a PRLR-
independent mechanism [68].
The molecular mechanisms by which PRL regulates pituitary
homeostasis during the estrous cycle are unknown. Since different
PRLR isoforms exhibit different capabilities to activate intracel-
lular signaling pathways [4,37,38], the ultimate effects of PRL
depend not only on the number, but also on the type of receptor
isoforms expressed in target tissues. It is thus important to
determine the pattern of PRLR expression before moving further
in intracellular signaling investigations. In the present study we
show that the anterior pituitary from female mice expresses short
and long PRLR isoforms and that expression of both are increased
at proestrus. This suggests that PRLR expression in the anterior
pituitary is regulated by circulating hormones whose levels
fluctuate during the estrous cycle. One of them is PRL itself,
which may regulate its own functions by modulating the
expression of its own receptor. Accordingly, we showed that
PRL inhibits expression of its receptor, as PRLR blockade in
female mice resulted in increased expression of PRLRlong and
PRLRshort isoforms, which is reminiscent to what we recently
reported for male anterior pituitary [24]. It has been previously
reported that the main PRLR isoform expressed in anterior
pituitaries from prepuberal female mice was PRLRshort and that
PRL treatment increased the expression of both isoforms of the
receptor [44]. The absence of estrous cycle in those young animals
could explain the discrepancies with our findings. In another
study, metoclopramide-induced hyperprolactinemia was reported
to not alter pituitary PRLR expression in either OVX or intact
female mice [45]. However, since the latter study did not
discriminate PRLR expression at the various stages of the estrous
cycle, it is possible that the levels of PRLR that were reported
actually represent an average throughout the estrous cycle which
may have masked the effect of PRL specifically at proestrus.
At proestrus, the increase of PRLRshort expression by far
exceeds that of PRLRlong, resulting in a nearly 1:1 ratio. The
functional outcome and physiological relevance of such a complex
regulation of PRLR expression are currently unknown. In fact, the
Figure 7. PRLR antagonism increases the expression of the long and short isoforms of PRLR. A, B: Body weight and pituitary weight of
WT and TGD1–9-G129R-hPRL mice, euthanized at diestrus or proestrus ‘p,0.05 vs. respective WT at diestrus or proestrus. Two-way ANOVA followed by
Tukey’s test. C, D: Expression of PRLR isoforms in the anterior pituitary from WT and TGD1–9-G129R-hPRL mice, euthanized at diestrus or proestrus. Real
Time PCR was performed using specific primers for long and short (S1, S2, S3) PRLR isoforms. The S1 short isoform was not detected. Each column
represents the relative increment 6 SEM with respect to the expression of PRLRlong (C) or PRLRshort (D) in control animals (WT mice at diestrus) (n$
5 animals/group). *p,0.05 vs. respective diestrus, ‘p,0.0.5 and ‘‘p,0.01 vs. respective WT at diestrus. Two-way ANOVA, followed by Tukey’s test.
doi:10.1371/journal.pone.0097383.g007
Table 2. PRLRlong/PRLRshort ratios at proestrus or diestrus in WT and TG animals.
WT TGD1–9-G129R-hPRL
DIESTRUS PROESTRUS DIESTRUS PROESTRUS
36.0:1 1.2:1 57.0:1 2.5:1
doi:10.1371/journal.pone.0097383.t002
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shift from a large excess of PRLRlong (diestrus) to similar amounts
of long and short isoforms (proestrus) presumably participates in
the proapoptotic effect of PRL at proestrus. Although PRL has
been shown to be proapoptotic in other tissues or cell types (e.g.
keratinocytes, chondrocyte, human myeloma-derived cell
lines)[50], the apoptotic signaling mechanism has not been
described so far for PRLR. The canonical signaling cascade of
the PRLR, namely the Jak2/STAT5 cascade, has been reported in
some instance to lead to proapoptotic responses by regulating the
expression of Bcl-2 family proteins [38,69]. However, as
PRLRshort has been shown to exert dominant negative effect for
the activation of Jak2/STAT5 by PRLRlong [70], it is unlikely that
the increase of PRLRshort expression favors such a mechanism to
induce apoptosis at proestrus. Clearly, elucidating intracellular
mechanisms underlying the proapoptotic effect of PRL at
proestrus requires careful investigation during the reproductive
cycle using acute PRL stimulation and genetic models as used in
this study; this is currently under investigation in our laboratories.
Our results suggest that a failure in PRLR-triggered proapop-
totic and antiproliferative effects may play a role in pituitary
tumorigenesis. Indeed, it has been reported that human prolacti-
nomas have decreased PRLR expression [71] and that a
nonfunctional mutation of the PRLR gene may be related to the
presence of microadenomas [72].
In conclusion, our studies show that PRL participates in the
control of anterior pituitary cell turnover maintaining pituitary
homeostasis throughout the estrous cycle. Hence, we propose that
chronic lack of physiological proapoptotic and antiproliferative
actions of PRL, and/or changes in PRLR expression, could
contribute to alterations in anterior pituitary cell renewal, leading
to pituitary hyperplasia and, eventually, tumor development.
Acknowledgments
We wish to thank Sophie Berissi, Christine Kayser and the personnel of the
Animal Core Facility of the Necker Faculty, Paul Kelly and Marianela
Candolfi for helpful discussions, Mercedes Insem and Cristina Deparci
from Instituto de Investigaciones Biome´dicas and Pla´cida Blas and Ariel
Billordo, form Laboratorio de Inmunogene´tica from Hospital de Clı´nicas
‘‘Jose´ de San Martı´n’’ Universidad de Buenos Aires, for their competence.
Author Contributions
Conceived and designed the experiments: JF DP VG NB JA SZ GJ AS.
Performed the experiments: JF SZ GJ JA MB FB. Analyzed the data: JF
DP VG. Contributed reagents/materials/analysis tools: VG NB AS DP.
Wrote the paper: JF DP VG.
References
1. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL)
and its receptor: actions, signal transduction pathways and phenotypes observed
in PRL receptor knockout mice. Endocr Rev 19: 225–268.
2. Ben-Jonathan N, LaPensee CR, LaPensee EW (2008) What can we learn from
rodents about prolactin in humans? Endocr Rev 29: 1–41.
3. Fernandez I, Touraine P, Goffin V (2010) Prolactin and human tumourogenesis.
J Neuroendocrinol 22: 771–777.
4. Bernichtein S, Touraine P, Goffin V (2010) New concepts in prolactin biology.
J Endocrinol 206: 1–11.
5. Goffin V, Hoang DT, Bogorad RL, Nevalainen MT (2011) Prolactin regulation
of the prostate gland: a female player in a male game. Nat Rev Urol 8: 597–607.
6. Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of
prolactin in mammary carcinoma. Endocr Rev 24: 1–27.
7. Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, et al. (2010) Local
prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.
Proc Natl Acad Sci U S A 107: 15199–15204.
8. Melmed S (2011) Pathogenesis of pituitary tumors. Nature reviews Endocrinol-
ogy 7: 257–266.
9. Dworakowska D, Grossman AB (2009) The pathophysiology of pituitary
adenomas. Best Pract Res Clin Endocrinol Metab 23: 525–541.
10. Candolfi M, Zaldivar V, Jaita G, Seilicovich A (2006) Anterior pituitary cell
renewal during the estrous cycle. Front Horm Res 35: 9–21.
Figure 8. Proposed model of anterior pituitary apoptosis modulation during the estrous cycle. During proestrus the surge of circulating
estradiol (E2) (1) increases PRL secretion (2) which, together with E2 itself induces apoptosis of anterior pituitary cells (AP) (3, 39). PRL stimulates
hypothalamic (4) dopamine (DA) release (5) which also contributes to the apoptosis observed in the gland at this stage of the estrous cycle (6). PP:
Posterior Pituitary.
doi:10.1371/journal.pone.0097383.g008
Prolactin Induces Apoptosis of Lacotropes
PLOS ONE | www.plosone.org 12 May 2014 | Volume 9 | Issue 5 | e97383
11. Chiu S, Koos RD, Wise PM (1992) Detection of prolactin receptor (PRL-R)
mRNA in the rat hypothalamus and pituitary gland. Endocrinology 130: 1747–
1749.
12. Morel G, Ouhtit A, Kelly PA (1994) Prolactin receptor immunoreactivity in rat
anterior pituitary. Neuroendocrinology 59: 78–84.
13. Brockman JL, Schroeder MD, Schuler LA (2002) PRL activates the cyclin D1
promoter via the Jak2/Stat pathway. Mol Endocrinol 16: 774–784.
14. Shiu RP, Elsholtz HP, Tanaka T, Friesen HG, Gout PW, et al. (1983) Receptor-
mediated mitogenic action of prolactin in a rat lymphoma cell line.
Endocrinology 113: 159–165.
15. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, et al.
(1997) Prolactin and prolactin receptors are expressed and functioning in human
prostate. J Clin Invest 99: 618–627.
16. Buckley AR (2001) Prolactin, a lymphocyte growth and survival factor. Lupus
10: 684–690.
17. DeVito WJ, Okulicz WC, Stone S, Avakian C (1992) Prolactin-stimulated
mitogenesis of cultured astrocytes. Endocrinology 130: 2549–2556.
18. Huang C, Snider F, Cross JC (2009) Prolactin receptor is required for normal
glucose homeostasis and modulation of beta-cell mass during pregnancy.
Endocrinology 150: 1618–1626.
19. Krown KA, Wang YF, Ho TW, Kelly PA, Walker AM (1992) Prolactin isoform
2 as an autocrine growth factor for GH3 cells. Endocrinology 131: 595–602.
20. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, et al. (1997) Pituitary
lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2
receptor-deficient mice. Neuron 19: 103–113.
21. Saiardi A, Bozzi Y, Baik JH, Borrelli E (1997) Antiproliferative role of dopamine:
loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia.
Neuron 19: 115–126.
22. Cruz-Soto ME, Scheiber MD, Gregerson KA, Boivin GP, Horseman ND (2002)
Pituitary tumorigenesis in prolactin gene-disrupted mice. Endocrinology 143:
4429–4436.
23. Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, et al. (2002) Lack of
prolactin receptor signaling in mice results in lactotroph proliferation and
prolactinomas by dopamine-dependent and -independent mechanisms. J Clin
Invest 110: 973–981.
24. Ferraris J, Boutillon F, Bernadet M, Seilicovich A, Goffin V, et al. (2012)
Prolactin receptor antagonism in mouse anterior pituitary: effects on cell
turnover and prolactin receptor expression. Am J Physiol Endocrinol Metab
302: E356–364.
25. Zarate S, Zaldivar V, Jaita G, Magri L, Radl D, et al. (2010) Role of estrogens in
anterior pituitary gland remodeling during the estrous cycle. Front Horm Res
38: 25–31.
26. Childs AJ (2006) Gonadotropes and Lactotropes. In: Neill JD, Physiology of
Reproduction: Elsiever.
27. Nolan LA, Kavanagh E, Lightman SL, Levy A (1998) Anterior pituitary cell
population control: basal cell turnover and the effects of adrenalectomy and
dexamethasone treatment. J Neuroendocrinol 10: 207–215.
28. Oishi Y, Okuda M, Takahashi H, Fujii T, Morii S (1993) Cellular proliferation
in the anterior pituitary gland of normal adult rats: influences of sex, estrous
cycle, and circadian change. Anat Rec 235: 111–120.
29. Takahashi S, Okazaki K, Kawashima S (1984) Mitotic activity of prolactin cells
in the pituitary glands of male and female rats of different ages. Cell and tissue
research 235: 497–502.
30. Hashi A, Mazawa S, Kato J, Arita J (1995) Pentobarbital anesthesia during the
proestrous afternoon blocks lactotroph proliferation occurring on estrus in
female rats. Endocrinology 136: 4665–4671.
31. Zaldivar V, Magri ML, Zarate S, Jaita G, Eijo G, et al. (2009) Estradiol increases
the Bax/Bcl-2 ratio and induces apoptosis in the anterior pituitary gland.
Neuroendocrinology 90: 292–300.
32. Zarate S, Jaita G, Zaldivar V, Radl DB, Eijo G, et al. (2009) Estrogens exert a
rapid apoptotic action in anterior pituitary cells. Am J Physiol Endocrinol Metab
296: E664–671.
33. Radl DB, Ferraris J, Boti V, Seilicovich A, Sarkar DK, et al. (2011) Dopamine-
induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor.
PLoS One 6: e18097.
34. Radl DB, Zarate S, Jaita G, Ferraris J, Zaldivar V, et al. (2008) Apoptosis of
lactotrophs induced by D2 receptor activation is estrogen dependent.
Neuroendocrinology 88: 43–52.
35. Ferraris J, Radl DB, Zarate S, Jaita G, Eijo G, et al. (2011) N-terminal prolactin-
derived fragments, vasoinhibins, are proapoptoptic and antiproliferative in the
anterior pituitary. PLoS One 6: e21806.
36. Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure,
function, and regulation of secretion. Physiol Rev 80: 1523–1631.
37. Sangeeta Devi Y, Halperin J (2013) Reproductive actions of prolactin mediated
through short and long receptor isoforms. Mol Cell Endocrinol.
38. Binart N, Bachelot A, Bouilly J (2010) Impact of prolactin receptor isoforms on
reproduction. Trends Endocrinol Metab 21: 362–368.
39. Jabbour HN, Kelly PA (1997) Prolactin receptor subtypes: a possible mode of
tissue specific regulation of prolactin function. Rev Reprod 2: 14–18.
40. Clarke DL, Linzer DI (1993) Changes in prolactin receptor expression during
pregnancy in the mouse ovary. Endocrinology 133: 224–232.
41. Nagano M, Kelly PA (1994) Tissue distribution and regulation of rat prolactin
receptor gene expression. Quantitative analysis by polymerase chain reaction.
J Biol Chem 269: 13337–13345.
42. Binart N, Imbert-Bollore P, Baran N, Viglietta C, Kelly PA (2003) A short form
of the prolactin (PRL) receptor is able to rescue mammopoiesis in heterozygous
PRL receptor mice. Mol Endocrinol 17: 1066–1074.
43. Bouilly J, Sonigo C, Auffret J, Gibori G, Binart N (2012) Prolactin signaling
mechanisms in ovary. Mol Cell Endocrinol 356: 80–87.
44. Shao R, Nutu M, Weijdegard B, Egecioglu E, Fernandez-Rodriguez J, et al.
(2008) Differences in prolactin receptor (PRLR) in mouse and human fallopian
tubes: evidence for multiple regulatory mechanisms controlling PRLR isoform
expression in mice. Biol Reprod 79: 748–757.
45. Amaral VC, Maciel GA, Carvalho KC, Marcondes RR, Soares JM Jr, et al.
(2013) Metoclopramide-induced hyperprolactinemia effects on the pituitary and
uterine prolactin receptor expression. General and comparative endocrinology.
46. Devost D, Boutin JM (1999) Autoregulation of the rat prolactin gene in
lactotrophs. Mol Cell Endocrinol 158: 99–109.
47. Jahn GA, Daniel N, Jolivet G, Belair L, Bole-Feysot C, et al. (1997) In vivo study
of prolactin (PRL) intracellular signalling during lactogenesis in the rat: JAK/
STAT pathway is activated by PRL in the mammary gland but not in the liver.
Biol Reprod 57: 894–900.
48. Recouvreux MV, Guida MC, Rifkin DB, Becu-Villalobos D, Diaz-Torga G
(2011) Active and total transforming growth factor-beta1 are differentially
regulated by dopamine and estradiol in the pituitary. Endocrinology 152: 2722–
2730.
49. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, et al. (1997) Null
mutation of the prolactin receptor gene produces multiple reproductive defects
in the mouse. Genes Dev 11: 167–178.
50. Ferraris J, Bernichtein S, Pisera D, Goffin V (2013) Use of Prolactin Receptor
Antagonist to Better Understand Prolactin Regulation of Pituitary Homeostasis.
Neuroendocrinology.
51. Zarate S, Jaita G, Ferraris J, Eijo G, Magri ML, et al. (2012) Estrogens induce
expression of membrane-associated estrogen receptor alpha isoforms in
lactotropes. PLoS One 7: e41299.
52. Pisera D, Candolfi M, Navarra S, Ferraris J, Zaldivar V, et al. (2004) Estrogens
sensitize anterior pituitary gland to apoptosis. Am J Physiol Endocrinol Metab
287: E767–771.
53. Silveyra P, Catalano PN, Lux-Lantos V, Libertun C (2007) Impact of proestrous
milieu on expression of orexin receptors and prepro-orexin in rat hypothalamus
and hypophysis: actions of Cetrorelix and Nembutal. Am J Physiol Endocrinol
Metab 292: E820–828.
54. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
55. Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D, Diaz-Torga G
(2012) Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit
prolactinoma growth and recover active pituitary transforming growth factor-
beta1 (TGF-beta1). Endocrinology 153: 3861–3871.
56. Candolfi M, Zaldivar V, De Laurentiis A, Jaita G, Pisera D, et al. (2002) TNF-
alpha induces apoptosis of lactotropes from female rats. Endocrinology 143:
3611–3617.
57. Candolfi M, Jaita G, Zaldivar V, Zarate S, Ferrari L, et al. (2005) Progesterone
antagonizes the permissive action of estradiol on tumor necrosis factor-alpha-
induced apoptosis of anterior pituitary cells. Endocrinology 146: 736–743.
58. Jaita G, Zarate S, Ferrari L, Radl D, Ferraris J, et al. (2011) Gonadal steroids
modulate Fas-induced apoptosis of lactotropes and somatotropes. Endocrine 39:
21–27.
59. Jaita G, Candolfi M, Zaldivar V, Zarate S, Ferrari L, et al. (2005) Estrogens up-
regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology 146:
4737–4744.
60. Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor.
Endocr Rev 22: 724–763.
61. Flurkey K, Gee DM, Sinha YN, Wisner JR Jr, Finch CE (1982) Age effects on
luteinizing hormone, progesterone and prolactin in proestrous and acyclic
C57BL/6j mice. Biol Reprod 26: 835–846.
62. Michael SD (1976) Plasma prolactin and progesterone during the estrous cycle
in the mouse. Proc Soc Exp Biol Med 153: 254–257.
63. Zaldivar V, Magri ML, Zarate S, Jaita G, Eijo G, et al. (2011) Estradiol increases
the expression of TNF-alpha and TNF receptor 1 in lactotropes. Neuroendo-
crinology 93: 106–113.
64. Arzt E, Buric R, Stelzer G, Stalla J, Sauer J, et al. (1993) Interleukin involvement
in anterior pituitary cell growth regulation: effects of IL-2 and IL-6.
Endocrinology 132: 459–467.
65. Chesnokova V, Zhou C, Ben-Shlomo A, Zonis S, Tani Y, et al. (2013) Growth
hormone is a cellular senescence target in pituitary and nonpituitary cells. Proc
Natl Acad Sci U S A 110: E3331–3339.
66. Ma FY, Anderson GM, Gunn TD, Goffin V, Grattan DR, et al. (2005) Prolactin
specifically activates signal transducer and activator of transcription 5b in
neuroendocrine dopaminergic neurons. Endocrinology 146: 5112–5119.
67. Ma FY, Grattan DR, Goffin V, Bunn SJ (2005) Prolactin-regulated tyrosine
hydroxylase activity and messenger ribonucleic acid expression in mediobasal
hypothalamic cultures: the differential role of specific protein kinases.
Endocrinology 146: 93–102.
68. Clapp C, Aranda J, Gonza´lez C, Jeziorski MC, Martı´nez de la Escalera G (2006)
Vasoinhibins: endogenous regulators of angiogenesis and vascular function.
Trends in Endocrinology and Metabolism 301–307.
Prolactin Induces Apoptosis of Lacotropes
PLOS ONE | www.plosone.org 13 May 2014 | Volume 9 | Issue 5 | e97383
69. Stankiewicz TR, Loucks FA, Schroeder EK, Nevalainen MT, Tyler KL, et al.
(2012) Signal transducer and activator of transcription-5 mediates neuronal
apoptosis induced by inhibition of Rac GTPase activity. J Biol Chem 287:
16835–16848.
70. Berlanga JJ, Garcia-Ruiz JP, Perrot-Applanat M, Kelly PA, Edery M (1997) The
short form of the prolactin (PRL) receptor silences PRL induction of the beta-
casein gene promoter. Mol Endocrinol 11: 1449–1457.
71. Jin L, Qian X, Kulig E, Scheithauer BW, Calle-Rodrigue R, et al. (1997)
Prolactin receptor messenger ribonucleic acid in normal and neoplastic human
pituitary tissues. J Clin Endocrinol Metab 82: 963–968.
72. Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, et al. (2013) Mutant
prolactin receptor and familial hyperprolactinemia. N Engl J Med 369: 2012–
2020.
Prolactin Induces Apoptosis of Lacotropes
PLOS ONE | www.plosone.org 14 May 2014 | Volume 9 | Issue 5 | e97383
